Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Eli Lilly, Zentalis Pharma Partner to Study Selective Estrogen Receptor Degrader, Verzenio Combo

Eli Lilly, Zentalis Pharma Partner to Study Selective Estrogen Receptor Degrader, Verzenio Combo

Jul 27, 2020
|
staff reporter

NEW YORK – Clinical-stage biopharmaceutical company Zentalis Pharmaceuticals said on Monday that it is partnering with Eli Lilly to evaluate Zentalis' ZN-c5, an investigational oral selective estrogen receptor degrader (SERD), in combination with Lilly's CDK4/6 inhibitor abemaciclib (Verzenio), in patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Cancer

  1. Pfizer Pursuing Multiple Biomarker-Defined Cancer Indications in Coming Years

    Premium

  2. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

  3. Yufan Biotech, Abound Bio Partner on HPK1-Inhibiting CAR T-Cell Therapies

  4. FDA Approves Expanded Use for Roche Cytology Test in Patients With Cervical Cancer

  5. LabCorp's Covance Joins Tempus TIME Trial Program

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.